Search
Ranirestat
go.drugbank.com/drugs/DB05327InvestigationalRanirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels
Dabocemagene autoficel
go.drugbank.com/drugs/DB17878InvestigationalDabocemagene autoficel is an _ex vivo_, autologous cell-based gene therapy. It comprises autologous dermal fibroblasts genetically modified to express functional type VII collagen.
Benserazide
go.drugbank.com/drugs/DB12783ApprovedInvestigationalWhen levodopa is used by itself as a therapy for treating Parkinson's disease, its ubiquitous metabolism into dopamine is responsible for a resultant increase in the levels of circulating dopamine in the blood and to various extracerebra...
Recombinant stabilized RSV A prefusion F antigen
go.drugbank.com/drugs/DB18713ApprovedInvestigational[L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023.
NOV-002
go.drugbank.com/drugs/DB05393InvestigationalIt has been administered to over 10,000 patients, demonstrating clinical efficacy and excellent safety data.
Mycophenolate mofetil
go.drugbank.com/drugs/DB00688ApprovedInvestigationalA180799,A180805] Previously, mycophenolic acid (MPA) was administered to individuals with autoimmune diseases beginning in the 1970s, but was discontinued due to gastrointestinal effects and concerns over
Synonyms: 2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoateUndecylenic acid
go.drugbank.com/drugs/DB11117ApprovedSalts of undecylenate are found in topical over-the-counter or mixture products as antifungal agents.
Products: CVS Pharmacy Maximum Strength Antifungal Liquid with Aloe and Vitamin E, Fiore Rx Antifungal ProPenPlazomicin
go.drugbank.com/drugs/DB12615ApprovedHowever, acquired resistance of aminoglycosides may arise through over expression of efflux pumps and ribosomal modification by bacteria, which results from amino acid or rRNA sequence mutations [A33942
Vedolizumab
go.drugbank.com/drugs/DB09033ApprovedInvestigational[A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter.
Temozolomide
go.drugbank.com/drugs/DB00853ApprovedInvestigationalconsiderable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably develop resistance to these agents over